3 Stocks Including Kiniksa Pharmaceuticals International That May Be Priced Below Intrinsic Value Estimates

The United States market has experienced a positive trajectory, climbing 2.7% in the last 7 days and showing a 9.6% increase over the past year, with earnings forecasted to grow by 14% annually. In such an environment, identifying stocks that are potentially priced below their intrinsic value can be key for investors seeking opportunities that align with these promising growth trends.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Click here to see the full list of 189 stocks from our Undervalued US Stocks Based On Cash Flows screener.

Let's take a closer look at a couple of our picks from the screened companies.

Kiniksa Pharmaceuticals International (NasdaqGS:KNSA)

Overview: Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company that develops and commercializes novel therapies for diseases with unmet needs, focusing on cardiovascular indications globally, with a market cap of approximately $1.89 billion.

Operations: Kiniksa Pharmaceuticals International generates its revenue from developing and delivering therapeutic medicines, amounting to $481.17 million.

Estimated Discount To Fair Value: 38.6%

Kiniksa Pharmaceuticals International is trading at US$26.97, significantly below its estimated fair value of US$43.96, suggesting it may be undervalued based on cash flows. The company recently raised its 2025 revenue guidance to between US$590 million and US$605 million, reflecting strong financial performance with Q1 2025 revenue at US$137.79 million compared to US$79.86 million a year ago, and a net income turnaround from a loss of USD 17.7 million to an income of USD 8.54 million.

• Our expertly prepared growth report on Kiniksa Pharmaceuticals International implies its future financial outlook may be stronger than recent results.
• Click here to discover the nuances of Kiniksa Pharmaceuticals International with our detailed financial health report.

AngloGold Ashanti (NYSE:AU)

Overview: AngloGold Ashanti plc is a gold mining company with operations across Africa, Australia, and the Americas, and it has a market cap of approximately $20.48 billion.

Operations: The company's revenue primarily comes from its Metals & Mining segment, specifically Gold & Other Precious Metals, totaling $5.79 billion.

Estimated Discount To Fair Value: 19.7%

AngloGold Ashanti, trading at US$42.16, is below its estimated fair value of US$52.49, indicating potential undervaluation based on cash flows. The company's earnings are projected to grow faster than the market average at 19.9% annually. Recent strategic alliances, such as the expanded joint venture with Kincora Copper in Australia, enhance exploration opportunities and may bolster future revenue streams despite an unstable dividend history and past shareholder dilution concerns.

• Upon reviewing our latest growth report, AngloGold Ashanti's projected financial performance appears quite optimistic.
• Delve into the full analysis health report here for a deeper understanding of AngloGold Ashanti.

Equifax (NYSE:EFX)

Overview: Equifax Inc. is a data, analytics, and technology company with a market cap of $32.13 billion.

Operations: The company's revenue is derived from three primary segments: International ($1.36 billion), Workforce Solutions ($2.45 billion), and U.S. Information Solutions ($1.93 billion).

Estimated Discount To Fair Value: 39.8%

Equifax, currently trading at US$260.13, is significantly undervalued based on cash flows with an estimated fair value of US$432.42. Despite high debt levels, its earnings are expected to grow at 21.3% annually, outpacing the market average. Recent developments include a new share buyback program worth US$3 billion and a 28% dividend increase to US$0.50 per share for Q2 2025, reflecting robust financial strategies amidst moderate revenue growth forecasts.

• In light of our recent growth report, it seems possible that Equifax's financial performance will exceed current levels.
• Take a closer look at Equifax's balance sheet health here in our report.

Summing It All Up

• Investigate our full lineup of 189 Undervalued US Stocks Based On Cash Flows right here.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com